简介:瞄准:在微容器密度(MVD)和脉管的内皮生长的表情调查差别,并且在MVD之中探索关联在前列腺癌症(PCa)之间的因素(VEGF),VEGF-C和VEGFreceptor-3(VEGFR-3)纸巾和邻近的良性的纸巾,Jewett-Whitmore阶段,格利森分数和在PCa的前进的VEGF,VEGF-C和VEGFR-3的表情。方法:免疫组织化学的途径被采用在癌症区域和71个主要职业人员静电干扰腺癌标本的外部良性的区域检测CD34,VEGF,VEGF-C和VEGFR-3的表情。统计分析然后被执行根据试验性并且诊所数据。结果:都显著地与邻近的良性的上皮(P<0.01)相比在恶意的上皮/癌症房间在VEGF,VEGF-C和VEGFR-3的调整表情上面被发现。当在肿瘤区域(P<0.01)比较VEGF-C或VEGFR-3的表示时,在阶段D的病人在阶段A,B或C比病人有一个显著地更高的分数。另外,重要关联在Jewett-Whitmore阶段和VEGF-C之间被观察(r=0.738,P<0.01),临床的阶段和VEGFR-3(r=0.410,P<0.01),VEGF-C和格利森分数(r=0.401,P<0.01),VEGFR-3和格利森分数(r=0.581,P<0.001)并且MVD和VEGF(r=0.492,P<0.001)。结论:VEGF和VEGF-C的增加的表情仔细与PCa的前进被联系。为PCa前进的增加的VEGF表示的主要贡献到过起来调整MVD,它维持了肿瘤织物的生长优点。然而,VEGF-C和VEGFR-3的增加的表情的主要角色是提高lymphangiogenesis并且提供一条主要小径让癌症房间传播。
简介:Objective:Theexpressionofvascularendothelialgrowthfactor(VEGF)iscorrelatedtotheinvasionandmetastasisoftumorcellsinmanyclinicalcarcinomas.Inthisstudy,wedetectedsolubleVEGFlevelsinascitesandperitonealfluidandexploreditsclinicalsignificance.Methods:Atotalof91sampleswerecollectedanddividedinto5experimentalgroups:petitonealfluidofpatientswithbenign(n=10)andmalignantdisease(n=14),cirrhoticascites(n=36),tuberculousascites(n=8)andmalignantascites(n=23).Usingasandwichenzyme-linkedimmunoadsorbentassay,theconcentrationofsolubleVEGFwasmeasuredinascites(n=67)andpetitonealfluid(n=24).Results:VEGFlevelsinmalignantasciteswere640.74(264.81pg/ml,significantlyhigherthanthoseincirrhoticascites,tuberculousascitesandperitonealfluidofpatientswithbenignandmalignantdisease(P<0.01,separately).However,thedifferenceofVEGFlevelsamongthelatter4groupshadnostatisticsignificance(P>0.05),separately).Furthermore,VEGFlevelsinmalignantascitesfrompatientswithovariancancerwerehigherthanthosewithgastricandcoloncancer(P<0.01,respectively),whiletherewasnosignificantdifferencebetweengastriccancerandcoloncancer(P>0.05).UsingVEGFlevelof118.96pg/mlasaminimumcutofflimit,thesensitivityandspecificityofVEGFofthisassaytodiagnosemalignantasciteswere91.3%and73.9%respectively.Conclusion:TheelevatedlevelsofVEGFmaybeusefulasanindexindifferentialdiagnosisofbenignandmalignantascites.ItappearsthatVEGFplaysanimportantroleinmalignantascitesformation.
简介:摘要目的探讨内分泌腺来源的血管内皮生长因子(EG-VEGF)、血管内皮生长因子在多囊卵巢综合征(PCOS)中的表达及意义。方法选取2014年2月至2016年12月我院收集的PCOS组织(PCOS组),同时选取正常卵巢组织31例作为对照组,采用免疫组化法检测EG-VEGF和VEGF表达。结果PCOS组织中EG-VEGF在颗粒细胞、卵泡膜细胞及间质细胞胞浆中高表达,VEGF在颗粒细胞及卵泡细胞胞浆中高表达;PCOS组EG-VEGF、VEGF表达分别为(0.183±0.011)和(0.179±0.010),明显高于对照组(p<0.05);PCOS组EG-VEGF表达水平与VEGF表达水平呈负相关(r=-0.362,p<0.05),对照组EG-VEGF表达水平与VEGF表达水平无相关性(p>0.05)。结论EG-VEGF和VEGF在PCOS组织中高表达,与PCOS发生可能有一定的关系。
简介:Vascularendothelialgrowthfactor(VEGF)isprimarilyknownasaproangiogenicfactorandisoneofthemostimportantgrowthandsurvivalfactorsaffectingthevascularendothelium.However,recentstudieshaveshownthatVEGFalsoplaysavitalroleintheimmuneenvironment.InadditiontothetraditionalgrowthfactorroleofVEGFandVEGFreceptors(VEGFRs),theyhaveacomplicatedrelationshipwithvariousimmunecells.VEGFalsoreportedlyinhibitsthedifferentiationandfunctionofimmunecellsduringhematopoiesis.Dendriticcells(DCs),macrophages,andlymphocytesfurtherexpresscertaintypesofVEGFreceptors.VEGFcanbesecretedaswellbytumorcellsthroughtheautocrinepathwayandcanstimulatethefunctionofcancerstemness.ThisreviewwillprovideaparadigmshiftinourunderstandingoftheroleofVEGF/VEGFRsignalingintheimmuneandcancerenvironment.
简介:Objective:Tostudytheexpressionofvascularendothelialgrowthfactor(VEGF)andmicrovesseldensity(MVD)inesophagealsquamouscellcarcinoma(ESCC)andclarifytheassociationofVEGFexpressionwiththeangiogenesisandprognosticvalueofthisdisease.Methods:Eighty-twocaseswithprimaryESCCtreatedwithradicaloperationinDepartmentofSurgeryfromJan1981throughMay1994wereenrolled.VEGFexpressionandMVDvaluewereexaminedbyimmunohistochemicalstaining,thestreptavidin-biotinperoxidasecomplexmethod(SPmethod),usinganti-VEGFpolyclonalantibodyandanti-Factor-VIIIantibody,respectively.WealsoanalyzedtherelationshipbetweenVEGFexpressionandMVDvalueandpostoperativesurvivalrateofpatients.Results:Ofthe82cases,63.4%casesshowedpositiveforVEGFintumorcellsandthemedianofMVDintumorwas37(9-150)·mm-2.TherewasaclosecorrelationbetweenMVDandVEGF(P=0.001).The5-yearsurvivalrateofpatientswithlowandhighMVDwas34.1%and12.2%,respectively.The5-yearsurvivalratewas46.7%inpatientswithVEGF-negativetumorand11.5%inpatientswithVEGF-positivetumor.Thesedifferenceswerestatisticallysignificant(P=0.017andP<0.001,respectively).Conclusion:InESCC,angiogenesisismediatedmainlybyVEGFandVEGFmaybeassociatedwithtumorprogressionandincreasedmalignancyviaangiogenesis.
简介:Objective:TostudytheeffectofantisenseVEGFRNAonratC6gliomasinvivoandfindoutthefeasibilityofantiangiogenesistherapywithantisenseVEGFRNAformalignantgliomas.Methods:ParentalratC6gliomacellsandC6cellstransfectedwithantisenseVEGFcDNAwereimplantedintracerebrallyandsubcutaneouslyintoSDratsascontrolandtransfectedgroup.RatsbearingcerebralandsubcutaneousC6gliomasweretreatedwithantisenseVEGFcDNAastreatedgroupandsenseVEGFcDNAandemptyvectorascontroloftreatedgroup.Thegeneralmanifestation,survivaltime,MRIandhistopathologicalchangesofallratswereobserved.Thevolumeofsubcutaneouslyimplantedtumorswasdeterminedregularly.InsituhybridizationandimmunohistochemicalstainingwereusedfordetectionofVEGFgeneexpressionofgliomaswhilePCNAimmunostainingandTUNELmethodforexaminationofproliferationactivityandapoptosisofgliomas,respectively.Results:Thesurvivaloftheratsintransfectedandtreatedgroupwasprolonged.Thereweretworatssurvivingover90dinthetreatedgroupandtheirtumorsdisappeared.TheVEGFgeneexpression,thenumberofmicrovesselsandtheproliferationactivityweredecreasedandalargeamountofapoptoticcellscouldbefoundincerebralandsubcutaneousgliomasintreatedandtransfectedgroups.Conclusion:VEGFisoneofthecandidategenesforgenetherapyofmalignantgliomas.AntisenseVEGFRNAcombinedwithothertherapiesshouldbestudiedfurtherforenhancingthetherapeuticeffectofmalignantgliomas.
简介:摘要目的检测EBV相关胃癌(EBVassociatedgastriccarcinomas,EBVaGC)和与之匹配的EBV阴性胃癌(EBVnetativegastriccarcinomas,EBVnGC)VEGF的表达,同时检测EBV相关基因的表达,探讨它们在EBVaGCs发生发展中的作用。方法选取13例EBVaGCs、45例与之相匹配的EBVnGCs和58例相应癌旁组织作为研究对象,采用免疫组化技术检测VEGF蛋白的表达;RT-PCR和Southern杂交技术检测EBV相关基因(核抗原EBNA1和EBNA2编码基因,潜伏膜蛋白LMP1编码基因,早期基因BARF1和BHRF1)的表达。结果①癌组织VEGF阳性率为72.41%(42/58),明显低于相应癌旁组织87.93%(51/58)(P=0.022);EBVaGC组织中VEGF阳性表达率为84.61%(11/13),明显高于EBVnGC组织68.9%(31/45),两组间差别有统计学意义(χ2=3.928,P=0.047)②13例EBVaGCsEBNA1mRNA均为阳性,而EBNA2和LMP1mRNA均为阴性;早期基因中有6例BARF1表达阳性,2例BHRF1表达阳性。结论①EBVaGC及EBVnGC中高表达VEGF,但是EBVaGC中VEGF的表达与血管生成和淋巴结转移关系密切程度不如EBVnGC②EBVaGC组织中LMP1和EBNA2表达阴性,与c-myc的表达和细胞增殖无明显相关性,早期基因BARF1和BHRF1可通过转化细胞等作用促进肿瘤的发生发展。
简介:目的:测定肺癌患者血清中血管内皮生长因子(VEGF)的水平,探讨VEGF与肺癌发生发展及转移的关系。方法:采用酶联免疫方法(ELISA)检测47例肺癌患者血清VEGF水平,同时测定10例正常人血清作为对照。结果:肺癌患者血清VEGF水平(453.57±196.21)pg/mL明显高于对照组(257.62±104.14)pg/mL,差异十分显著(P<0.叭);VEGF水平与肺癌组织学类型、临床分期和分化程度无明显相关(P>0.05),但与淋巴结转移和远道转移密切相关;发生淋巴结转移和远道转移的患者VEGF水平高于未转移患者,差异有显著性(P<0.05)。结论;肺癌患者血清中VEGF水平在一定程度上可反映肿瘤生长、发展及转移趋势,对肺癌的临床综合治疗和预后判断可能具有重要应用价值。
简介:
简介:【摘要】 恶性胸腔积液即癌性胸腔积液,是胸膜原发肿瘤或肿瘤累及胸膜所产生的胸腔积液,是晚期肿瘤最常见的并发症之一。肺癌是引发恶性胸腔积液的主要原因,恶性胸腔积液增长速度较快,控制难度大,患者经常产生胸闷气短、呼吸抑制、肺部感染、肺不张等表现,不仅生活质量大受影响,生命也会面对较大的威胁,生存期甚至仅有 3 个月。目前,化疗是治疗恶性胸腔积液的主要方法之一,但是这种治疗方案仅能减少胸腔积液的产生,总体效果并不如意。好在近些年来人们对肿瘤生长转移与心血管形成之间的联系有了一定的认识,人们因此开始将研究热点专项血管内皮细胞生长因子 及其靶向药物。本文试对 VEGF 在肺癌恶性胸腔积液中表达进行分析研究。
简介:定量研究正常和放射复合伤口中VEGF基因表达及其在血管再生中的作用.方法48只wistar二级大鼠背部皮肤制作圆形伤口后以25Gy60Coγ射线局部照射,于伤后2、5、10、15、2l和28d活杀取材,采用免疫组化和图像分析技术研究VEGF基因表达及其意义.结果单创组于伤后2d,新生血管内皮细胞浆内VEGF呈强阳性;5d时毛细血管数明显增多,其内皮细胞浆内VEGF阳性;而于10d后,VEGF逐渐减少.伤照组则于伤后5d呈弱阳性,10d时阳性,15d后呈弱阳性.定量结果表明:单创组VEGF于伤后2-10d平均光密度(MOD)逐渐减少(P<0.05或P<0.01),积分光密度(IOD)逐渐增加(P<0.05或P<0.01).15d后其MOD和IOD均明显减少.伤照组VEGF的MOD和IOD(P<0.01)于伤后10d达高峰.照射组与单创组比,伤后5-10d,其MOD和IOD均明显减少(P<0.05或P<0.01);伤后15d,其IOD较单创组为多(P<0.05).结论内源性VEGF基因表达参与创伤愈合中血管再生过程;辐射使血管内皮细胞表达VEGF减少,强度减弱,时间滞后.